A recent surveillance study in Korea revealed that 14% (7/50) of Aspergilus flavus clinical isolates had a voriconazole minimum inhibitory concentration ≥ 4 µg/mL. Of seven non-wild-type (non-WT) isolates, six ear isolates from four hospitals shared the same microsatellite genotype. None of non-WT isolates showed cyp51 mutations associated with azole resistance. However, the mean expression levels of efflux pumps (MDR2, atrF, and mfs1) and target (cyp51A) genes exhibited significant differences between non-WT and other isolates.
https://ift.tt/2QheWsu
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου